MX2009007329A - 1,3-dihidroimidazoles para tratar trastornos cardiovasculares. - Google Patents
1,3-dihidroimidazoles para tratar trastornos cardiovasculares.Info
- Publication number
- MX2009007329A MX2009007329A MX2009007329A MX2009007329A MX2009007329A MX 2009007329 A MX2009007329 A MX 2009007329A MX 2009007329 A MX2009007329 A MX 2009007329A MX 2009007329 A MX2009007329 A MX 2009007329A MX 2009007329 A MX2009007329 A MX 2009007329A
- Authority
- MX
- Mexico
- Prior art keywords
- halogen
- alkyl
- group
- term
- alkyloxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de un compuesto de la fórmula I, en donde R1, R2 y R3 son los mismos o diferentes y significan grupos hidrógeno, halógeno, alquilo, alquilarilo, alquiloxi, hidroxi, nitro, amino, alquilcarbonilamino, alquilamino o dialquilamino; R4 significa grupos hidrógeno, alquilo o alquilarilo; X significa CH2, un átomo de oxígeno o un átomo de azufre; n es 1, 2 o 3, con la condición que cuando n sea 1, X no es CH2; los enantiómeros individuales (R) y (S) o mezclas de enantiómeros y sales farmacéuticamente aceptables de los mismos; en donde el término alquilo significa cadenas de hidrocarburo, rectas o ramificadas, que contienen de uno a seis átomos de carbono, sustituidas opcionalmente por grupos arilo, alcoxi, halógeno, alcoxicarbonilo o hidroxicarbonilo; el término arilo significa un grupo fenilo o naftilo, sustituido opcionalmente por un grupo alquiloxi, halógeno o nitro; el término halógeno significa flúor, cloro, bromo o yodo, en la manufactura de un medicamento para el tratamiento de una o más de las siguientes indicaciones insuficiencia cardíaca congestiva, angina, arritmias, trastornos circulatorios tal como el fenómeno de Raynaud, migraña y trastornos de ansiedad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700635.6A GB0700635D0 (en) | 2007-01-12 | 2007-01-12 | Therapy |
| PCT/PT2008/000001 WO2008085074A2 (en) | 2007-01-12 | 2008-01-10 | 1, 3-dihydroimidazoles for treating cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009007329A true MX2009007329A (es) | 2009-07-15 |
Family
ID=37809883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009007329A MX2009007329A (es) | 2007-01-12 | 2008-01-10 | 1,3-dihidroimidazoles para tratar trastornos cardiovasculares. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100286219A1 (es) |
| EP (1) | EP2111262A2 (es) |
| JP (1) | JP2010515726A (es) |
| KR (1) | KR20090100443A (es) |
| CN (1) | CN101600474A (es) |
| AR (1) | AR064869A1 (es) |
| AU (1) | AU2008204006A1 (es) |
| BR (1) | BRPI0806514A2 (es) |
| CA (1) | CA2674305A1 (es) |
| GB (1) | GB0700635D0 (es) |
| MX (1) | MX2009007329A (es) |
| RU (1) | RU2009130726A (es) |
| WO (1) | WO2008085074A2 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2919780T1 (sl) * | 2012-11-14 | 2018-12-31 | Bial - Portela & Ca., S.A. | Derivati 1,3-dihidroimidazol-2-tiona za uporabo v zdravljenju pljučne arterijske hipertenzije in poškodbe pljuč |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
-
2007
- 2007-01-12 GB GBGB0700635.6A patent/GB0700635D0/en not_active Ceased
-
2008
- 2008-01-10 JP JP2009545511A patent/JP2010515726A/ja active Pending
- 2008-01-10 KR KR1020097016624A patent/KR20090100443A/ko not_active Application Discontinuation
- 2008-01-10 BR BRPI0806514-4A patent/BRPI0806514A2/pt not_active IP Right Cessation
- 2008-01-10 WO PCT/PT2008/000001 patent/WO2008085074A2/en active Application Filing
- 2008-01-10 US US12/522,525 patent/US20100286219A1/en not_active Abandoned
- 2008-01-10 CA CA002674305A patent/CA2674305A1/en not_active Abandoned
- 2008-01-10 CN CNA2008800020370A patent/CN101600474A/zh active Pending
- 2008-01-10 RU RU2009130726/15A patent/RU2009130726A/ru unknown
- 2008-01-10 EP EP08705171A patent/EP2111262A2/en not_active Withdrawn
- 2008-01-10 AU AU2008204006A patent/AU2008204006A1/en not_active Abandoned
- 2008-01-10 MX MX2009007329A patent/MX2009007329A/es not_active Application Discontinuation
- 2008-01-11 AR ARP080100134A patent/AR064869A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008085074A3 (en) | 2008-12-11 |
| CN101600474A (zh) | 2009-12-09 |
| WO2008085074A8 (en) | 2009-01-29 |
| EP2111262A2 (en) | 2009-10-28 |
| WO2008085074A2 (en) | 2008-07-17 |
| AU2008204006A8 (en) | 2009-08-27 |
| CA2674305A1 (en) | 2008-07-17 |
| KR20090100443A (ko) | 2009-09-23 |
| US20100286219A1 (en) | 2010-11-11 |
| GB0700635D0 (en) | 2007-02-21 |
| AR064869A1 (es) | 2009-04-29 |
| AU2008204006A1 (en) | 2008-07-17 |
| BRPI0806514A2 (pt) | 2011-09-13 |
| RU2009130726A (ru) | 2011-02-20 |
| JP2010515726A (ja) | 2010-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200716084A (en) | Methods for treating sleep-wake disorders | |
| AR112789A2 (es) | COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| EA201101089A1 (ru) | Производные оксадиазола в качестве агонистов рецептора s1p1 | |
| MY144960A (en) | Morpholine type cinnamide compound | |
| ECSP055633A (es) | Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos | |
| TW200745034A (en) | New compounds | |
| MX2009009384A (es) | Malonamidas como antagonistas de orexina. | |
| CY1116391T1 (el) | Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5 | |
| TW200727893A (en) | Methods for treating sexual dysfunction | |
| MY168283A (en) | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | |
| RU2012155118A (ru) | Способы лечения биполярного расстройства | |
| CR8854A (es) | Nuevos d-homo-estra-1,3,5 (10)-trienos sustituidos en la posicion 2 como inhibidores de 17b-hidroxiesteroide deshidrogenasa tipo 1 | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| EA201070010A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
| MX2009010727A (es) | Heterociclos como antagonistas de orexina. | |
| TW200740760A (en) | Malonamide derivatives | |
| CY1120953T1 (el) | Παραγωγα 1,3-διυδροϊμιδαζολο-2-θειονης για χρηση στην αγωγη πνευμονικης αρτηριακης υπερτασης και πνευμονικης βλαβης | |
| MX2009007329A (es) | 1,3-dihidroimidazoles para tratar trastornos cardiovasculares. | |
| GB2483195A (en) | Novel uses | |
| AR095674A2 (es) | INHIBIDORES PERIFÉRICAMENTE SELECTIVOS DE DOPAMINA-b-HIDROXILASA Y MÉTODO PARA SU PREPARACIÓN | |
| CY1113458T1 (el) | Σπειρο (πιπεριδιν-4, 2'-πυρρολιδιν)-1-(3,5 τριφθορομεθυλ φαινυλ) μεθυλκαρβοξαμιδια ως ανταγωνιστες του υποδοχεα ταχυκινινης νκ1 | |
| PL1776339T3 (pl) | Pochodne 3-(((-4-fenylo)-piperazyn-1-ylo)-alkilo)-3-alkilo-1,3-dihydro-2H-indol-2-onu i związki pokrewne do leczenia chorób centralnego układu nerwowego | |
| DE602007012683D1 (de) | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente | |
| MX2016003211A (es) | Procesos para la preparacion de medicamentos para el tratamiento de enfermedades cardiovasculares y compuestos intermedios para uso en los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |